(MENAFN- Baystreet.ca) More revolutionary news on the health-care front: Eatontown, New Jersey-based American CryoStem Corporation (OTC:CRYO) saw its stock shoot through the roof Wednesday, on word of its application to the U.S. Food and Drug Administration (FDA).
The company, a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, announced today that it has submitted its first Investigational New Drug Application for its ATCell™ product to the FDA.
The federal body's acceptance for review of CryoStem's IND application is a 'significant milestone' for the company and represents a meaningful step forward in the treatment of patients suffering from Post Concussion Syndrome. It also aids in the advancement of Regenerative Medicine.
CRYO's Phase I Clinical Trial, upon FDA approval, will investigate ATCell™ to provide assessments of the safety and tolerability, and to collect clinical data regarding the alleviation of symptoms associated with Post-Concussion Syndrome.
Stock prices were healthy, though, climbing five cents, or 11.6%, to 48 cents, on volume of 46,000
MENAFN1809201902120000ID1099022016
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.